Reliance Life Sciences is developing novel therapeutics for treatment of cancer, infectious diseases, inflammatory disorders, ocular disorders and neurodegenerative disorders. The discovery program is based on siRNAs and monoclonal antibodies.

Small interference RNA (siRNA) based drugs gained importance because of their unique mechanism of action and ease of targeting a number of hitherto unmet medical needs. The approaches for the discovery program are to identify small interference RNA (siRNA) for various target genes and develop drugs through preclinical and clinical studies. A number of target genes have been identified. siRNAs have been designed and are currently in the process of evaluation both in vitro and in vivo.

In the domain of monoclonal antibodies, a number of validated targets have been identified for the development of antibody-based therapeutics. These targets are both cell surface receptors and soluble proteins, which are implicated in cancer and inflammatory diseases.

Through these research activities, the company aims at bringing cost-effective therapies for the benefit of the global population